Financials Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-07-04 pm EDT			5-day change	1st Jan Change
11.81 ^CNY	+5.07%		-0.59%	-21.27%

Jul. 01	Nanjing King-Friend Biochemical Pharma Registers Regadenoson Injection in China; Shares Up 3%	MT
Jun. 28	NKFPharma's Unit Buys Yusimry's Rights for $40 Million	MT

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	29,701	32,706	52,058	29,075	24,169	19,017	-	-
Enterprise Value (EV) ¹	29,701	32,706	52,058	29,075	24,169	19,017	19,017	19,017
P/E ratio	49.4 x	40.4 x	47.7 x	26.9 x	-125 x	21 x	14 x	11.8 x
Yield	-	-	-	-	-	-	-	-
Capitalization / Revenue	12 x	11.2 x	14.1 x	7.83 x	6.15 x	4.34 x	3.34 x	2.81 x
EV / Revenue	12 x	11.2 x	14.1 x	7.83 x	6.15 x	4.34 x	3.34 x	2.81 x
EV / EBITDA	41.7 x	32 x	40.8 x	22.1 x	22.7 x	14.8 x	10.5 x	8.93 x
EV / FCF	-	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-	-
Price to Book	10 x	9.2 x	9.8 x	4.77 x	4.22 x	2.9 x	2.29 x	1.97 x
Nbr of stocks (in thousands)	1,573,132	1,573,368	1,611,324	1,611,717	1,611,291	1,610,277	-	-
Reference price ²	18.88	20.79	32.31	18.04	15.00	11.81	11.81	11.81
Announcement Date	4/29/20	4/26/21	4/26/22	4/27/23	4/26/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	2,470	2,915	3,687	3,713	3,931	4,377	5,688	6,758
EBITDA ¹	712.6	1,021	1,275	1,313	1,062	1,288	1,804	2,130
EBIT ¹	667.6	877	1,182	1,174	-294.7	1,043	1,554	1,854
Operating Margin	27.03%	30.09%	32.06%	31.61%	-7.5%	23.82%	27.33%	27.43%
Earnings before Tax (EBT) ¹	680.4	914.6	1,204	1,185	-294.8	1,047	1,561	1,858
Net income ¹	605	806.1	1,059	1,091	-189.4	908.9	1,242	1,609
Net margin	24.5%	27.66%	28.73%	29.38%	-4.82%	20.76%	21.84%	23.82%
EPS ²	0.3823	0.5148	0.6769	0.6700	-0.1200	0.5625	0.8440	0.9975
Free Cash Flow	-	-	-	-	-	-	-	-
FCF margin	-	-	-	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-	-	-
Announcement Date	4/29/20	4/26/21	4/26/22	4/27/23	4/26/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow	-	-	-	-	-	-	-	-
ROE (net income / shareholders' equity)	22.5%	24.5%	25.3%	18.8%	-3.17%	13.8%	16.2%	16.7%
ROA (Net income/ Total Assets)	-	-	-	-	-1.94%	9%	10.8%	12.4%
Assets ¹	-	-	-	-	9,767	10,099	11,504	12,979
Book Value Per Share ²	1.880	2.260	3.300	3.790	3.560	4.080	5.150	5.990
Cash Flow per Share ²	-0.5300	-0.3600	0.4200	0.3700	1.000	0.1400	0.2600	0.3300
Capex ¹	115	294	440	470	419	350	410	451
Capex / Sales	4.66%	10.09%	11.94%	12.66%	10.66%	7.99%	7.21%	6.68%
Announcement Date	4/29/20	4/26/21	4/26/22	4/27/23	4/26/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.81 CNY

Average target price

16.78 CNY

Spread / Average Target

+42.13%

	1st Jan change	Capi.
NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD.	-21.27%	2.49B
ELI LILLY AND COMPANY	+56.89%	809B
NOVO NORDISK A/S	+39.52%	624B
JOHNSON & JOHNSON	-6.55%	351B
ABBVIE INC.	+7.92%	289B
ASTRAZENECA PLC	+13.74%	240B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	166B
PFIZER, INC.	-2.57%	157B